Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors
Investigator
Trial Phase
Phase I
Study Number
NCT03037385
Local Study ID
20172740
Trial Contact Phone
800-804-8824 / 206-606-1024
Summary
This is a Phase 1, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of BLU-667 administered orally in patients with NSCLC, thyroid cancer and other solid tumors.
Trial Eligibility
*For Eligibility information, look up the trial at NIH by clicking on the Study Number above.*
Other eligibility criteria may apply.
Trial Exclusions
Other exclusion criteria may apply.
Trial Keywords
Colon Cancer; Head and Neck Cancer; Lung Cancer; Solid Tumors; Thyroid Cancer; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Bronchogenic; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Adenocarcinoma; Carcinoma, Neuroendocrine; Endocrine Gland Neoplasms; Neoplasms, Thoracic; Endocrine System Diseases; Respiratory Tract Diseases
See this trial at ClinicalTrials.gov

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.